Source comparison
Tesamorelin + Ipamorelin vs Other GH Protocols: Clinical Comparison
Tesamorelin + Ipamorelin Blend Dual-pathway (GHRH + ghrelin receptor) 15–18% at 26 weeks (clinical trial data) 30–40% above baseline, sustained 6–8 hours No cortisol or prolactin elevation Daily or twice daily (subcutaneous) Most physiologically balanced. Mimi
This comparison does not assign a generated winner or score.
- Tesamorelin + Ipamorelin Blend
- Dual-pathway (GHRH + ghrelin receptor)
- 15–18% at 26 weeks (clinical trial data)
- 30–40% above baseline, sustained 6–8 hours
- No cortisol or prolactin elevation
- Daily or twice daily (subcutaneous)
- Most physiologically balanced. Mimics natural pulsatile GH without hormone disruption. Gold standard for visceral fat targeting.
- GHRP-2
- Ghrelin receptor agonist
- Minimal direct fat reduction
- 50–70% peak, short duration (2–3 hours)
- Moderate cortisol and prolactin elevation
- Twice or three times daily
- Produces higher GH spikes than ipamorelin but disrupts cortisol rhythm and stimulates appetite. Less selective receptor activity.
- CJC-1295 + Ipamorelin
- GHRH analog + ghrelin receptor
- Moderate (10–12%)
- 40–50% sustained 5–6 hours
- No cortisol elevation
- Twice weekly (DAC version) or daily (no-DAC)
- Comparable GH elevation to tesamorelin blend but lacks FDA-validated visceral fat data. DAC version extends half-life but risks receptor desensitisation.
- MK-677 (Ibutamoren)
- Oral ghrelin mimetic
- Minimal visceral targeting
- 60–80% peak, inconsistent pulsatility
- Moderate cortisol elevation, insulin resistance risk
- Once daily (oral)
- Convenience of oral administration but produces non-pulsatile GH elevation and significant appetite increase. Not suitable for fat loss protocols.
- Exogenous rhGH
- Direct GH replacement
- High (dose-dependent)
- Supraphysiological levels (200–400% baseline)
- Complete suppression of endogenous GH production
- Daily injections
- Most potent for GH elevation but shuts down natural production, expensive, and carries higher side effect profile (joint pain, edema, insulin resistance).